The problem. The treatment. Special situations. Brief background on HBV Definitions of HBV reactivation. The role and timing of antiviral therapy
|
|
- Molly Dalton
- 5 years ago
- Views:
Transcription
1 Pr Raymond Sayegh
2 The problem Brief background on HBV Definitions of HBV reactivation The treatment The role and timing of antiviral therapy Special situations Lone anti-hbcpositive, rituximab, BMT, reactivation in nononcology settings
3 Immunotolerance HBV DNA Immune Clearance Immune Control (Nonreplicative) HBeAg+ HBsAg+ ALT HBeAg- HBeAb+ HBsAg- HBsAb Yrs Mos-Yrs Infection Yim HJ, et al. Hepatology. 2006;43:S173-S181. Mos-Yrs
4 Immunotolerance HBV DNA HBeAg+ HBsAg+ ALT Immune Clearance Immune Control (Nonreplicative) Most Oncology Patients Normal ALT Low/undetectable HBV DNA HBsAg+ and HBeAg- or HBsAg-, anti-hbc+ HBeAg- HBeAb+ HBsAg- HBsAb Yrs Mos-Yrs Infection Yim HJ, et al. Hepatology. 2006;43:S173-S181. Mos-Yrs
5 cccdna Immune control not clearance Resolved HBV a misnomer still HBV DNA in liver Werle-Lapostolle B, et al. Gastroenterology. 2004;126:
6 cccdna Immune control not clearance Resolved HBV a misnomer still HBV DNA in liver Werle-Lapostolle B, et al. Gastroenterology. 2004;126:
7 T cell cccdna T cell T cell Immune control not clearance Resolved HBV a misnomer still HBV DNA in liver Werle-Lapostolle B, et al. Gastroenterology. 2004;126:
8 T cell cccdna T cell HIV Steroids Chemotx T cell Immune control can be lost Immune-mediated liver damage with immune reconstitution Werle-Lapostolle B, et al. Gastroenterology. 2004;126:
9 T cell cccdna T cell HIV Steroids Chemotx T cell Immune control can be lost Immune-mediated liver damage with immune reconstitution Werle-Lapostolle B, et al. Gastroenterology. 2004;126:
10 HBeAg+ HBeAg- HBeAb+ HBeAg+ Immunotolerance Immune Clearance HBV DNA ALT Infection 5-30 Yrs Mos-Yrs Hoofnagle JH. Hepatology. 2009;49(5 suppl):s156-s165. Mos-Yrs
11 HBeAg+ HBeAg- HBeAb+ HBeAg+ Immunotolerance Immune Clearance Immune Suppression HBV DNA ALT Infection 5-30 Yrs Mos-Yrs Hoofnagle JH. Hepatology. 2009;49(5 suppl):s156-s165. Mos-Yrs
12 HBeAg+ HBeAg- HBeAb+ HBeAg+ Immunotolerance Immune Clearance Immune Suppression Immune Reconstitution HBV DNA ALT Infection 5-30 Yrs Mos-Yrs Mos-Yrs Hoofnagle JH. Hepatology. 2009;49(5 suppl):s156-s165.
13 Definition Loss of HBV immune control in a patient with inactive or resolved HBV infection Abrupt reappearance or increase in viral replication with liver damage occurring during and/or following immune reconstitution Clinically Range from subclinical to severe/fatal hepatitis Rise in HBV DNA ±return of HBeAg ALT increase (may be mild or very dramatic) May progress to liver failure/death despite antiviral therapy Hoofnagle JH. Hepatology. 2009;49(5 suppl):s156-s165.
14 Class Corticosteroids Antitumor antibiotics Plant alkaloids Alkylating agents Antimetabolites Monoclonal antibodies Others Agents Dexamethasone, methylprednisolone, prednisolone Actinomycin D, bleomycin, daunorubicin, doxorubicin, epirubicin, mitomycin-c Vinblastine, vincristine Carboplatin, chlorambucil, cisplatin, cyclophosphamide, ifosfamide Azauridine, cytarabine, fluouracil, gemcitabine, mercaptopurine, methotrexate, thioguanine Alemtuzumab, rituximab Colaspase, docetaxel, etoposide, fludarabine, folinic acid, interferon, procarbazine Yeo W, et al. Hepatology. 2006;43:
15 25 HBV DNA Bilirubin ALT Hepatology consulted Chemotherapy Lamivudine 2500 HBV DNA (Log IU/mL) Bilirubin (mg/dl) ALT (IU/L) Wks Despite introduction of lamivudine, patient died of liver failure 0
16 Hepatitis May be severe or even fulminant Occasionally may miss HBV DNA spike because HBV DNA may fall when ALT rises This may lead to misdiagnosis and, ultimately, may result in subsequent flares of HBV By the time ALT rises... may be too late to bring under control Interruption of chemotherapy Potential for poorer cancer-related outcome Yeo W, et al. Hepatology. 2006;43:
17 HBsAg-positive breast cancer patients receiving chemotherapy Rate of HBV-associated acute hepatitis: 21% [1] With careful HBV DNA monitoring, up to 41% with HBV reactivation [2] HBV DNA may be undetectable by time of ALT peak Limited data on other solid tumors Of those who flare [2] : 35% chemotherapy interruption 35% premature termination of chemotherapy 1. Kim MK, et al. Korean J Intern Med. 2007;22: Yeo W, et al. J Med Virol. 2003;70:
18 100 patients with NHL undergoing CHOP; 27 HBsAg positive HBsAg Patients (%) HBV Reactivation Jaundice 4 4 Nonfatal Liver Failure Death Lok AS, et al. Gastroenterology. 1991;100:
19 Malignancy NHL: 40% to 58% of HBsAg positive Breast cancer: up to 41% of HBsAg positive Chemotherapy Prednisone, anthracyclines, rituximab increased risk Potency of immunosuppression HBV DNA HBV DNA > copies/ml Elevated if HBeAg positive Demographics Men > women Yeo W, et al. Hepatology. 2006;43:
20 50 patients with NHL who were HBsAg positive randomized to epirubicin, cyclophosphamide and etoposide (ACE) ± prednisolone (P) HBsAg Patients (%) * HBV Reactivation 13 44* ALT > 10 x ULN 4 Jaundice * 28* Complete Remission Survival at 4 Yrs ACE PACE *P <.05 Cheng AL, et al. Hepatology. 2003;37: Prednisolone increased risk and severity of HBV reactivation but trend toward improved NHL outcome
21
22 HBsAg-positive patients with lymphoma treated with high-dose chemotherapy randomized to preemptive vs on-demand lamivudine Survival Free From Hepatitis Due to HBV Reactivation Pts at Risk, n Preemptive LAM On-demand LAM 100 Lau GK, et al. Gastroenterology. 2003;125: P=.002 by log-rank test Preemptive LAM On-demand LAM (if HBV DNA increased) Wk
23 HBV DNA (Log IU/mL)/ Bilirubin (mg/dl) Cycloph/doxo Lamivudine Paclitaxel ALT (IU/L) HBV DNA Bilirubin ALT Hepatology consulted Wks Uninterrupted chemotherapy with no hepatitis flare
24 HBsAg-positive patients with NHL treated with CHOP randomized to preemptive vs on-demand lamivudine HBsAg Patients (%) Hsu C, et al. Hepatology. 2008;47: On-demand group: start LAM if ALT > 1.5 x ULN Preemptive group: start LAM on Day 1 of CHOP 48 8 HBV Reactivation and Hepatitis Flare 36 0 HBV Reactivation and ALT >10 x ULN HBV Reactivation and Jaundice Preemptive antivirals decrease HBV reactivation Death (After ChemoTx)
25 Choice of therapy affected by HBV DNA level HBV DNA < 2000 IU/mL: any therapy can be used (including lamivudine) HBV DNA > 2000 IU/mL: entecavir or tenofovir Choice of therapy affected by duration of therapy > 12 mos: entecavir or tenofovir HBV DNA and ALT should be monitored every 3 mos EASL. J Hepatol. 2009;50: Lok AS, et al. Hepatology. 2009;50:
26 When to start Ideally before or together with chemotherapy Do not delay start of chemotherapy When to stop If baseline HBV DNA > 2000 IU/mL: high risk of withdrawal flare Continue therapy as for chronic HBV infection If baseline HBV DNA < 2000 IU/mL 6-12 mosafter end of chemotherapy Monitor for withdrawal flares with monthly HBV DNA and ALT EASL. J Hepatol. 2009;50: Lok AS, et al. Hepatology. 2009;50:
27
28 Indicates exposure to HBV Usually persists lifelong but may lose after yrs May be false positive if truly no HBV risk factors No guidelines for management Risk for reactivation Low risk for most standard solid tumor regimens Consider preemptive HBV therapy if cirrhosis Consider preemptive HBV therapy if the following treatment strategies are used Rituximab Bone marrow/stem cell transplantation Manzano-Alonso ML, et al. World J Gastroenterol. 2011;17:
29 Monoclonal antibody against CD20 (B-cell marker) Reduces B-cell numbers and antibody levels Increasingly used as part of CHOP-R, EPOCH-R Increased risk of HBV reactivation, including HBsAgnegative patients Reverse seroconversion: reappearance of HBsAg in previously HBsAg-negative patient due to loss of immune control Yeo W, et al. Hepatology. 2006;43: Papamichalis P, et al. Clin Res Hepatol Gastroenterol. 2012;36:84-93.
30 Patients with diffuse large B-cell lymphoma HBsAg-negative, anti-hbc positive individuals treated with CHOP or CHOP-R Proportion of Anti-HBcPositive, HBsAg-Negative Patients (%) HBV Reverse Seroconversion Yeo W, et al. J Clin Oncol. 2009;27: HBV-Related Death CHOP (n = 25) CHOP-R (n = 21) Risk of reactivation with rituximab significant in anti-hbc positive 5
31 Reverse HBV seroconversion [1] Among 5 patients who reactivated, 1 during fifth cycle of chemotherapy; 3 median of 98 days AFTER last rituximab cycle; can occur early as well Median peak ALT: 809 U/L ( ) Median peak bilirubin: 65 µmol/l (19-249) Risk Factors for reactivation 1. Men >> women (almost all cases) 2. Anti-HBs negative (or low titer) 3.? increased age (> 50 yrs) Yeo W, et al. J Clin Oncol. 2009;27:
32 Markedly high rate of reactivation (HBsAg positive) Up to 54% [1] need preemptive antiviral therapy! Long-term complications: cirrhosis in 10% [2] Reverse seroconversion common if anti-hbc positive [3] Up to 50% become HBsAg positive use preemptive antivirals May occur very late HBV status of donor important [1,4] If natural immunity (anti-hbs, anti-hbc): may clear HBsAg If vaccinated (anti-hbs): possibly some protection 1. Lau GK, et al. Bone Marrow Transplant. 1997;19: Hui CK, et al. Blood. 2005;106: Onozawa M, et al. Transplantation. 2005;79: Lau GK, et al. J Infect Dis. 1998;178:
33 HBV reactivation not uncommon in HBsAg-positive individuals treated with standard chemotherapy HBV may reactivate even in those with an apparent resolved infection (anti-hbc positive, HBsAg negative) Greatest risk factor for HBV is country of origin Highest reactivation risk with rituximab and stemcell/bmt HBV reactivation can be effectively prevented with preemptive antiviral therapy
34 Preemptive therapy requires preemptive screening, which is highly cost-effective Screening recommended by CDC, EASL, AASLD, and IOM Patients to receive Standard chemotherapy Screen HBsAg (± anti-hbc) Patients to receive Complex chemotherapy (eg, rituximab/ BMT) Screen HBsAg, anti-hbc, anti-hbs Management of lone anti-hbcpositive controversial; follow-up required
35 HBsAg Significance Action HBV infection Prophylaxis indicated Anti-HBs alone Immunity to HBV None Anti-HBc + anti-hbs - Exposure to HBV If HBsAg negative, low risk for standard chemotherapy If BMT or rituximab, consider prophylaxis HBV DNA Undetectable < 2000 IU/mL 2000 IU/mL Very low HBV DNA Low HBV DNA High HBV DNA Lamivudine adequate Lamivudine adequate Consider more potent agent
36 Increasing use of biologics and immunomodulatory therapies Rheumatology (systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc) Dermatology (psoriasis, pemphigus) Gastroenterology (irritable bowel syndrome, autoimmune hepatitis) Data on incidence and management limited Case reports only
37 Anti-TNF (infliximab, adalimumab, etanercept) Other (rituximab, cyclosporine) Antimetabolite (methotrexate) Immunomodulatory Therapy Steroids (prednisone, budesonide) Purine Analogues (azathioprine/6mp) Roche B, et al. Liver Int. 2011;31(suppl 1):
38 HBsAg+ HBV DNA Screen all patients HBsAg, anti-hbc, anti-hbs Positive HBsAg-, anti-hbc+ HBV DNA < 2000 IU/mL 2000 IU/mL Positive Negative LAM x 6-12 mos posttherapy ETV/TDF until HBV endpoints Test HBsAg q mo HBV DNA q 3 mos Until 6-12 mos posttherapy Watch for withdrawal flares *Caveats: If concern about monitoring err on side of treatment High risk: anti-hbs negative older men consider up-front treatment
39 Increased use of immunomodulatorytherapy in nononcology fields HBV reactivation reported with many agents but absolute risks unclear Recommend screening all for HBsAg and anti-hbc HBsAg-positive patients should receive preemptive antiviral therapy Lone anti-hbcpositive: management less clear
40
ESCMID Online Lecture Library. by author
Immunosuppression and Hepatitis B Virus Reactivation Prof. Hakan Leblebicioglu, MD hakan@omu.edu.tr www.leblebicioglu.org Immunotolerance Immune Clearance HBV reactivation HBeAg+ HBeAg- HBeAb+ HBV DNA
More informationHBV Reactivation: A Preventable Menace
HBV Reactivation: A Preventable Menace Raymond T Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research Grant Support Gilead
More informationImmunosuppression and HBV Reactivation Associate Professor Joe Sasadeusz
Immunosuppression and HBV Reactivation Associate Professor Joe Sasadeusz Mr BR 40 yo man originally from New Caledonia PH complex, chronic perianal fistula Nov 2008 Diagnosed with MALT lymphoma in colonic
More informationESCMID Online Lecture Library. by author
Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline
More informationHepatitis B Reactivation
Hepatitis B Reactivation IOM, December 1 st, 2015 Rohit Loomba, MD, MHSc Professor of Medicine, Division of Gastroenterology and Adjunct Professor, Division of Epidemiology University of California at
More information26/09/2014. Chronic HBV Infection (n = >370 million world-wide n = 218,000 in Australia) HBV REACTIVATION
Chronic HBV (n = >37 million world-wide n = 218, in Australia) HBV REACTIVATION PLAYING WITH FIRE Maggie Bassendine 5-3 Yrs HBV (up to 2 billion people world-wide, up to 2 million in Australia) 5-3 Yrs
More informationCHB worldwide. HBeAg. Organ, blood, and semen donors HBV DNA. Hemodialysis ALT. Immune tolerant 1,2
CHB worldwide Chronic Hepatitis B: Taming an Old Dog with New Tricks Approximately 35 million people worldwide have CHB 1,2 High prevalence areas include regions of 2,3 : Asia Africa Eastern Europe The
More informationManagement of HBV in Challenging Populations
Management of HBV in Challenging Populations K. Rajender Reddy, M.D. Ruimy Family President s Distinguished Professor in Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationChemotherapy-induced HBV reactivation in cancer patients
Chemotherapy-induced HBV reactivation in cancer patients On behalf of Taiwan Cooperative Oncology Group (TCOG) HBV reactivation in lymphoma patients: What we have known HBV reactivation and hepatitis flares
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More informationManagement of immunocompromised patients with chronic or resolved HBV infection
Management of immunocompromised patients with chronic or resolved HBV infection Evangelos Cholongitas Assistant Professor 4 th Department of Internal Medicine Medical School of Aristotle University, Thessaloniki,
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More information6/9/2015. Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD Director, Schiff Center for Liver Diseases University of Miami
Grant/Research Support: AbbVie, BMS, Gilead, Merck, Orasure Technologies, Roche Molecular, Janssen, Discovery Life Sciences, Beckman Coulter, Inc., Siemens Corporation, MedMira Inc., Conatus Eugene R.
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationOccult Hepatitis B viral infection (OBI) in patients on chemotherapy
Occult Hepatitis B viral infection (OBI) in patients on chemotherapy Dr Cheung Wing-i Associate Consultant Our Lady of Maryknoll Hospital Hong Kong Association for the Study of Liver Diseases Annual Scientific
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationDiscontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?
More informationOccult Hepatitis B Infection: why, who and what to do?
Occult Hepatitis B Infection: why, who and what to do? MF Yuen, MD, PhD Chair of Gastroenterology and Hepatology Department of Medicine The University of Hong Kong Queen Mary Hospital, Hong Kong Who? Different
More information8 Larissa International Congress of Internal Medicine
8 Larissa International Congress of Internal Medicine Larissa, 18 th March 2016 IBD & Viral Hepatitis Alessio Aghemo, MD, PhD Division of Gastroenterology and Hepatology Fondazione IRCCS Ca Granda Ospedale
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationHepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis
Critical Reviews in Oncology/Hematology 87 (2013) 12 27 Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis Mario Mandalà a,, Stefano Fagiuoli b, Daniela Francisci
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationHepatitis B Virus Reactivation After Cytotoxic Chemotherapy: The Disease and Its Prevention
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1076 1081 REVIEW Hepatitis B Virus Reactivation After Cytotoxic Chemotherapy: The Disease and Its Prevention AYSE L. MINDIKOGLU, ARIE REGEV, and EUGENE R.
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationInvestigation into withdrawal of entecavir after 20 months in an HBsAb-positive patient who received HBsAg allogeneic stem cell transplantation
Investigation into withdrawal of entecavir after 20 months in an HBsAb-positive patient who received HBsAg allogeneic stem cell transplantation J. Peng, W.F. Luo, B. Zhou and W.Q. Wen Department of Infectious
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationAnti-HBc: state of the art what is the CORE of the issues?
Anti-HBc: state of the art what is the CORE of the issues? Robert G Gish MD Adjunct Professor Stanford University Medical Director Hepatitis B Foundation Disclosures: See robertgish.com If you wish an
More informationClinical Case Maria Butí, MD, PhD
Clinical Case Maria Butí, MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital 1 Clinical Case 70 year-old male Smoker, no alcohol intake No risk factors Diabetes Mellitus treated with
More informationPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v22.i28.6484 World J Gastroenterol 2016 July 28; 22(28): 6484-6500 ISSN 1007-9327 (print)
More informationHBeAg-negative chronic hepatitis B. with a nucleos(t)ide analogue?
4 th PARIS HEPATITIS CONFERENCE HBeAg-negative chronic hepatitis B Why do I treat my chronic hepatitis B patients with a nucleos(t)ide analogue? George V. Papatheodoridis, MD 2nd Department of Internal
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationESCCMID OLL. by Author. Hepatitis in immunocompromised hosts. Treviso, July 5, Saverio G Parisi
Hepatitis in immunocompromised hosts Treviso, July 5, 2011 Saverio G Parisi Department of Histology, Microbiology and Medical Biotechnology Università di Padova HBV Virological categories Persistent HBV
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationHCV e HBV nelle malattie oncologiche
INFEZIONI DA HBV E HCV PROBLEMATICHE ATTUALI Cagliari, 7 Dicembre 2018 HCV e HBV nelle malattie oncologiche Marta Muntoni, MD UOC Oncologia Medica AOBrotzu, P.O. Businco - Cagliari - INTRODUCTION Ø Chemotherapy-induced
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationWHAT DO ALL THESE HAVE IN COMMON WITH HUMANS?
WHAT DO ALL THESE HAVE IN COMMON WITH HUMANS? HEPATITIS B Anju Sidhu MD University of Louisville Gastroenterology, Hepatology and Nutrition August 25, 2011 OVERVIEW Understanding the Markers Natural History
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationCase Report Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations
Case Reports in Hepatology Volume 2013, Article ID 454897, 5 pages http://dx.doi.org/10.1155/2013/454897 Case Report Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHow to treat HCV-HBV co-infection?
How to treat HCV-HBV co-infection? Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białymstoku Paris Hepatology Conference, 14-15 january 219 Conflict od interest
More informationLesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy
References 1 Okoli K, Gupta A, Irani F, Kasmani R. Immune thrombocytopenia associated with Mycoplasma pneumoniae: a case report and review of literature. Blood Coagul Fibrinolysis 2009;20:595 8. 2 Izumikawa
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationCase Report Bortezomib Induced Hepatitis B Reactivation
Case Reports in Medicine, Article ID 964082, 5 pages http://dx.doi.org/10.1155/2014/964082 Case Report Bortezomib Induced Hepatitis B Reactivation Salwa Hussain, 1 Ruby Jhaj, 1 Samira Ahsan, 1 Muhammad
More informationBackground. ΝΑ therapy in CHBe- until HBsAg clearance. (EASL guidelines 2012)
Interferon-induced protein 10 (IP10) at discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy cannot predict subsequent relapses in non-cirrhotic HBeAgnegative chronic hepatitis B (CHBe-)
More informationSpontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report
Hara et al. Surgical Case Reports (2016) 2:118 DOI 10.1186/s40792-016-0246-2 CASE REPORT Open Access Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationHepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v21.i36.10274 World J Gastroenterol 2015 September 28; 21(36): 10274-10289 ISSN 1007-9327
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationThe natural course of chronic HBV infection can be divided into four, which are not always continuous.
HEPATITIS B Hepatitis B is a major global health problem. The WHO reports that there are 350 million carriers worldwide. This disease is the leading cause of liver cancer in the world and frequently leads
More informationAdmissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014
Hepatol Int (2016) 10:139 146 DOI 10.1007/s12072-015-9659-4 ORIGINAL ARTICLE Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014 Arpan
More informationShort title: BENEFIT STUDY, STUDY REPORT (ML25614) Synopsis/Abstract
A Multicenter, prospective, Non-Interventional Study Evaluating Response Parameters during and after Therapy with PEGASYS (Peginterferon alfa-2a 40KD) in Subjects with HBeAg positive or HBeAg negative
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationNegative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma
Al-Mansour et al. Infectious Agents and Cancer (2018) 13:18 https://doi.org/10.1186/s13027-018-0190-9 RESEARCH ARTICLE Open Access Negative effect of hepatitis in overall and progression-free survival
More informationHepatitis B New Therapies
Hepatitis B New Therapies Richard K. Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF VCU Hepatology Professor of Medicine Chief, Section of Hepatology Fellowship Director, Transplant Hepatology Virginia Commonwealth
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
More informationHepatitis B in HIV Patients. Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center
Hepatitis B in HIV Patients Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center Learning Objectives Identify tests to diagnoses HBV active infection, resolved infection, and need for immunization
More informationTreatment of Hepatitis B
Treatment of Hepatitis B Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Medical Director, Liver Transplantation Indiana University Health Indiana University School of
More informationBeyond the Tip of the Iceberg: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy
: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy Sunday, November 1, 2009 Back Bay Ballroom Sheraton Boston Hotel Boston, Massachusetts This program is supported by an educational
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationChemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients With Resolved HBV Infection: A Prospective Study
VIRAL HEPATITIS Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients With Resolved HBV Infection: A Prospective Study Chiun Hsu, 1,2 Hsiao-Hui Tsou, 3 Shyh-Jer Lin, 4 Ming-Chung Wang, 5 Ming
More informationFarmaci biologici e avventi avversi: Epatite B. Giammarco Mocci SC di Gastroenterologia Azienda Ospedaliera G. Brotzu - Cagliari
Farmaci biologici e avventi avversi: Epatite B Giammarco Mocci SC di Gastroenterologia Azienda Ospedaliera G. Brotzu - Cagliari Biologic agent for Rheumatoid Arthritis MTX- naive approval OPPORTUNISTIC
More informationConsiderations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection
Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection Mahnaz Arian, MD Assistant Professor in infectious Disease Mashhad university of Medical
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More information